Addition and Correction pubs.acs.org/molecularpharmaceutics
Correction to “Intranuclear Drug Delivery and Effective in Vivo Cancer Therapy via Estradiol−PEG-Appended Multiwalled Carbon Nanotubes” Manasmita Das, Raman Preet Singh, Satyajit R. Datir, and Sanyog Jain* Mol. Pharmaceutics 2013, 10 (9), 3404−3416. DOI: 10.1021/mp4002409
T
he authors regret having provided an incorrect image for Figure 2A. Specifically, the confocal image presented in Figure 2A under E2+ in this article represents a different delivery system (folic acid-conjugated MWCNTs) reported in a different article.1 The corrected image is provided herein. The authors sincerely apologize for overlooking the discrepancy in the original article and any inconvenience that might have been caused to the readers due to this.
Figure 2. (A) Confocal laser scanning images of MCF 7 cells treated with E2-PEG-MWCNTs in the absence (top three panels) and the presence of E2 (bottom three panels). For each incubation type, panels a, b, and c represent DAPI fluorescence, RITC fluorescence, and overlay of RITC and DAPI fluorescence, respectively.
■
REFERENCES
(1) Das, M.; Datir, S. R.; Singh, R. P.; Jain, S. Augmented Anticancer Activity of a Targeted, Intracellularly Activatable, Theranostic Nanomedicine Based on Fluorescent and Radiolabeled, Methotrexate-Folic Acid-Multiwalled Carbon Nanotube Conjugate. Mol. Pharmaceutics 2013, 10 (7), 2543−2557.
Published: January 19, 2016 © 2016 American Chemical Society
698
DOI: 10.1021/acs.molpharmaceut.5b00964 Mol. Pharmaceutics 2016, 13, 698−698
